• (no title)
• A comprehensive review on the current status of CRISPR based clinical trials for rare diseases
• A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
• A human centred innovative approach based on persona in hereditary angioedema
• A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema
• Altered levels of phospholipases C, diacylglycerols, endocannabinoids, and N-acylethanolamines in patients with hereditary angioedema due to FXII mutation
• An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema
• An LNP-CRISPR Gene Editing Drug Demonstrates Efficacy and Safety in Hereditary Angioedema Patients Following In Vivo Administration
• An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration
• An Overview of Hereditary Angioedema for the Primary Care Physician
• Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series
• Anesthetic management with remimazolam for a patient with hereditary angioedema:a case report
• Angiotensin-Converting Enzyme Inhibitors and Other Medications Associated With Angioedema
• Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments
• Assessment of clinical phenotypic characteristics of patients with angioedema without wheals in a turkish population
• Cardiovascular Autonomic Nervous System in a Patient With Hereditary Angioedema Affected by COVID-19
• Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy
• Case series of hereditary angioedema patients and use of tranexamic acid treatments in prophylaxis and acute crisis, experience in Peru
• Centralized care model for hereditary angioedema overcomes geographical barriers
• Classification, Diagnosis, and Pathology of Angioedema Without Hives
• Clinical development of anti-FXII therapeutics as a target in thrombo-inflammation
• Clinical features and potential markers of disease in idiopathic non-histaminergic angioedema, a real-life study
• Complex analysis of the national Hereditary angioedema cohort in Slovakia - Identification of 12 novel variants in SERPING1 gene
• Contact System Activation and Bradykinin Generation in Angioedema: Laboratory Assessment and Biomarker Utilization
• COVID-19 and vaccination in hereditary angioedema: Single center experience
• Current and Emerging Therapeutics in Hereditary Angioedema
• DAB2IP associates with hereditary angioedema: Insights into the role of VEGF signaling in HAE pathophysiology
• Danazol's use for menstrual suppression in transgender individuals: A retrospective multi-site cohort study
• Deciphering the landscape of hereditary angioedema in India: Perspective for Indian dermatologists
• Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
• Design and implementation of a transdisciplinary care model for patients with hereditary angioedema, in a Colombian health institution
• Determinants of Disease Activity in Adults With Hereditary Angioedema due to C1-Esterase Inhibitor Deficiency
• Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial
• Development and Validation of a US HAE-C1INH Quality of Life Instrument
• Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein
• Disparities in geography and race in hereditary angioedema: Analysis of 64 trials & 4354 patients
• Disparities in geography and race in hereditary angioedema: Analysis of 64 trials and 4354 patients
• Efficacy and Safety of Donidalorsen for Hereditary Angioedema
• Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review
• Exploring disease-specific metabolite signatures in hereditary angioedema patients
• Exploring the spectrum of allergic disorders that continue to challenge the Allergist-Immunologist: From hereditary angioedema to metal implant allergy
• Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity
• Extremely Late Diagnosis of Hereditary Angioedema Type I in an Elderly Female
• Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
• Hereditary angioedema classification: Expanding knowledge by genotyping and endotyping
• Hereditary Angioedema Exacerbated by Estrogen Supplementation Treatment for Uterine Fibroid: A Therapeutic Challenge
• Hereditary angioedema in Spain: medical care and patient journey
• Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia
• Hereditary Angioedema Type 1 and 2 in Finland: Incidence, Prevalence, and Preceding Diagnoses
• Hereditary angioedema with a normal C1 inhibitor in Japanese man
• Hereditary angioedema with normal C1 esterase inhibitor: Current paradigms and clinical dilemmas
• Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency
• Hereditary Angioedema: A Rare Cause of Acute Pancreatitis
• Hereditary angioedema: beyond swelling
• Hereditary angioedema: current therapeutic management and future approaches
• Hereditary or acquired? Comprehensive genetic testing assists in stratifying angioedema patients
• Impact of Sulfonamide Allergy Label on Clinical Outcomes in Patients with Pneumocystis jirovecii Pneumonia
• In vivo CRISPR agent cuts HAE attacks 95
• Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study
• Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) as a compensatory protease inhibitor in hereditary angioedema
• Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) as a Compensatory Protease Inhibitor in Hereditary Angioedema (HAE)
• Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema
• Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
• Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema
• Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials
• Long term outcome of C1-esterase inhibitor deficiency
• Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents
• Long-term prophylactic therapy combined with on-demand therapy for the control of hereditary angioedema--Comment on the 2021 edition of the international WAO/EAACI guideline for the management of hereditary angioedema
• Mast cell degranulation and bradykinin-induced angioedema - searching for the missing link
• Navigating the swells: A case report of hereditary angioedema
• New Therapies for Type 1 and Type 2 Hereditary Angioedema
• Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema
• Novel genetic modifiers of the clinical phenotype in patients with hereditary angioedema due to C1 inhibitor deficiency
• Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
• Pediatric hereditary angioedema attack triggered by COVID-19: A case report
• Perioperative management of a patient with hereditary angioedema undergoing oral surgery
• Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study
• Plasminogen missense variants and their involvement in cardiovascular and inflammatory disease
• Prodromal symptoms of hereditary angioedema (HAE) attacks: A patient survey in UK and Spain
• Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus
• Psychometric evaluation of the multidimensional Uraemic Pruritus in Dialysis patients (UP-Dial) scale: comparison of haemodialysis and peritoneal dialysis patients with chronic pruritus
• Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances
• Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system
• Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)
• Registry of Members of the Association of Patients with Hereditary Angioedema of Peru
• Selection of initiatives to improve the management of patients with hereditary angioedema by the hospital pharmacy using the nominal group technique
• Structural basis for the inhibition of βFXIIa by garadacimab
• Successful Pregnancy Outcome in a Hereditary Angioedema Patient With Previous Pregnancy Losses: A Proposed Delivery Plan
• Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema
• The Burden of Hereditary Angioedema in a Large Family in Brazil
• The CC2D2B is a novel genetic modifier of the clinical phenotype in patients with hereditary angioedema due to C1 inhibitor deficiency
• The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
• The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks
• The Definition, Acronyms, Nomenclature, and Classification of Angioedema: AAAAI, ACAAI, ACARE, and APAACI DANCE Consensus
• The Disease Burden of Hereditary Angioedema: Insights from a Survey in French-Canadians from Quebec
• The effect of estrogen-containing birth control pills on the constituents of bradykinin expression in plasma
• The future of therapeutic options for hereditary angioedema
• The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center
• Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration
• Validation and correlations of the Angioedema Activity Score (AAS), Angioedema Quality of Life (AE-QoL) questionnaire, and Angioedema Control Test (AECT) in Chinese patients with angioedema